Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA) an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince Youn H Kim; Steven M Horwitz; Reinhard Dummer; Julia Scarisbrick; Pietro Quaglino; Pier Luigi Zinzani; Pascal Wolter; Jose A Sanches; Pablo L Ortiz-Romero; Oleg E Akilov; Larisa Geskin; Judith Trotman; Kerry Taylor; Stephane Dalle; Michael Weichenthal; Jan Walewski; David Fisher; Brigitte Dréno; Rudolf Stadler; Tatyana Feldman; Timothy MKuzel; Yinghui Wang; Maria Corinna Palanca-Wessels; Erin Zagadailov; William L Trepicchio; Wenwen Zhang; Hui-Min Lin; Yi Liu; Dirk Huebner; Meredith Little; Sean Whittaker; Madeleine Duvic
Lancet London v. 390, n. 10094, p. 555-566, 2017London 2017
Acesso online. A biblioteca também possui exemplares impressos.
- 0
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
bcsep 030 2012
bcsep 028 2012@5
browse_callnumber
display.do?gathStatTab=true&dscnt=0&callNumberBrowseField=browse_callnumber&tabRealType=browseshelf&mode=Basic&vid=USP&rfnGrp=1&rfnGrp=show_only&tab=default_tab&dstmp=1722451205157&rfnGrpCounter=1&fctV=Lancet&fctV=online_resources&callNumber=bcsep+029+2017&fctN=facet_jtitle&fctN=facet_tlevel&vl(freeText0)=Liu%2C%20Y.&ct=display&fn=search&indx=2&recIdxs=0&elementId=0